新型低剂量替米沙坦、氨氯地平和吲达帕胺三联单片复方制剂与双联组合治疗高血压的疗效和安全性:一项随机、双盲、活性对照、国际临床试验
这项国际随机双盲活性对照试验纳入1385例高血压患者,比较新型三联单片复方制剂GMRx2(替米沙坦、氨氯地平、吲达帕胺)与三种双联组合的疗效和安全性。结果显示GMRx2在降低家庭收缩压和诊室血压方面优于各双联组合,且耐受性良好。
要点
- GMRx2组第12周家庭收缩压较替米沙坦-吲达帕胺组降低2.5 mmHg(95%CI -3.7至-1.3,p<0.0001)。
- GMRx2组第12周诊室血压控制率(<140/90 mmHg)为74%,各双联组合为53-61%。
- 因不良事件退出治疗的比例各组间无显著差异。
核心结论
- 新型低剂量替米沙坦、氨氯地平和吲达帕胺单片复方制剂GMRx2与双联组合相比在降低血压方面提供有临床意义的改善,且耐受性良好。
- 该单片复方制剂为高血压管理提供了新的治疗选择,其使用可能在临床实践中带来血压控制的大幅改善。
研究设计与样本
- 国际、随机、双盲、活性对照试验,纳入澳大利亚、捷克共和国、新西兰、波兰、斯里兰卡、英国和美国的成人高血压患者。
- 纳入正在接受0至3种降压药物的成人高血压患者,筛选时收缩压范围:未用药者140-179 mmHg,用三种药者110-150 mmHg。
- 经过4周活性导入期将现有药物转换为GMRx2半剂量(替米沙坦20 mg、氨氯地平2.5 mg、吲达帕胺1.25 mg)后,按2:1:1:1随机分配至继续GMRx2半剂量组或各双联组合半剂量组。
- 第6周时所有组剂量加倍,除非有临床禁忌;主要疗效终点为基线至第12周家庭收缩压平均变化,主要安全终点为基线至第12周因不良事件退出治疗。
- 共随机分配1385例参与者:GMRx2组551例,替米沙坦-吲达帕胺组276例,替米沙坦-氨氯地平组282例,氨氯地平-吲达帕胺组276例;平均年龄59岁(SD 11),女性712例(51%),男性673例(48.6%)。
主要发现
- 第12周GMRx2组平均家庭收缩压为126 mmHg,较替米沙坦-吲达帕胺组降低2.5 mmHg(95%CI -3.7至-1.3,p<0.0001),较替米沙坦-氨氯地平组降低5.4 mmHg(95%CI -6.8至-4.1,p<0.0001),较氨氯地平-吲达帕胺组降低4.4 mmHg(95%CI -5.8至-3.1,p<0.0001)。
- 第12周诊室血压差异:GMRx2组较替米沙坦-吲达帕胺组降低4.3/3.5 mmHg,较替米沙坦-氨氯地平组降低5.6/3.7 mmHg,较氨氯地平-吲达帕胺组降低6.3/4.5 mmHg(所有p<0.001)。
- 第12周诊室血压控制率(<140/90 mmHg)GMRx2组为74%,优于各双联组合组(范围53-61%)。
- 因不良事件退出治疗:GMRx2组11例(2%),替米沙坦-吲达帕胺组4例(1%),替米沙坦-氨氯地平组3例(1%),氨氯地平-吲达帕胺组4例(1%),差异均无统计学显著性。
临床怎么用
- 作者认为,该单片复方制剂为高血压管理提供了新的治疗选择,其使用可能在临床实践中带来血压控制的大幅改善。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Single-pill combinations (SPCs) of three low-dose antihypertensive drugs can improve hypertension control but are not widely available. A key issue for any combination product is the contribution of each component to efficacy and tolerability. This trial compared a new triple SPC called GMRx2, containing telmisartan, amlodipine, and indapamide, with dual combinations of components for efficacy and safety. METHODS: In this international, randomised, double-blind, active-controlled trial, we enrolled adults with hypertension receiving between zero and three antihypertensive drugs, with a screening systolic blood pressure (SBP) ranging from 140-179 mm Hg (on no drugs) to 110-150 mm Hg (on three drugs). Participants were recruited from Australia, the Czech Republic, New Zealand, Poland, Sri Lanka, the UK, and the USA. In a 4-week active run-in, existing medications were switched to GMRx2 half dose (telmisartan 20 mg, amlodipine 2·5 mg, and indapamide 1·25 mg). Participants were then randomly allocated (2:1:1:1) to continued GMRx2 half dose or to each possible dual combination of components at half doses (telmisartan 20 mg with amlodipine 2·5 mg, telmisartan 20 mg with indapamide 1·25 mg, or amlodipine 2·5 mg with indapamide 1·25 mg). At week 6, doses were doubled in all groups, unless there was a clinical contraindication. The primary efficacy outcome was mean change in home SBP from baseline to week 12, and the primary safety outcome was withdrawal of treatment due to an adverse event from baseline to week 12. Secondary efficacy outcomes included differences in clinic and home blood pressure levels and control rates. This study is registered with ClinicalTrials.gov, NCT04518293, and is completed. FINDINGS: The trial was conducted between July 9, 2021 and Sept 1, 2023. We randomly allocated 1385 participants to four groups: 551 to GMRx2, 276 to telmisartan-indapamide, 282 to telmisartan-amlodipine, and 276 to amlodipine-indapamide groups. The mean age was 59 years (SD 11), 712 (51%) participants self-reported as female and 673 (48·6%) male, and the mean clinic blood pressure at the screening visit was 142/85 mm Hg when taking an average of 1·6 blood pressure medications. Following the run-in on GMRx2 half dose, the mean clinic blood pressure level at randomisation was 133/81 mm Hg and the mean home blood pressure level was 129/78 mm Hg. At week 12, the mean home SBP was 126 mm Hg in the GMRx2 group, which was lower than for each of the dual combinations: -2·5 (95% CI -3·7 to -1·3, p<0·0001) versus telmisartan-indapamide, -5·4 (-6·8 to -4·1, p<0·0001) versus telmisartan-amlodipine, and -4·4 (-5·8 to -3·1, p<0·0001) versus amlodipine-indapamide. For the same comparisons, differences in clinic blood pressure at week 12 were 4·3/3·5 mm Hg, 5·6/3·7 mm Hg, and 6·3/4·5 mm Hg (all p<0·001). Clinic blood pressure control rate below 140/90 mm Hg at week 12 was superior with GMRx2 (74%) to with each dual combination (range 53-61%). Withdrawal of treatment due to adverse events occurred in 11 (2%) participants in the GMRx2 group, four (1%) in telmisartan-indapamide, three (1%) in telmisartan-amlodipine, and four (1%) in amlodipine-indapamide, with none of the differences being statistically significant. INTERPRETATION: A novel low-dose SPC product of telmisartan, amlodipine, and indapamide provided clinically meaningful improvements in blood pressure reduction compared with dual combinations and was well tolerated. This SPC provides a new therapeutic option for the management of hypertension and its use could result in a substantial improvement in blood pressure control in clinical practice. FUNDING: George Medicines.
引用
- Rodgers A, Salam A, Schutte AE, et al. Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical trial. Lancet. 2024. PMID: 39426836. doi:10.1016/S0140-6736(24)01744-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。